Mesalazine and idiopathic intracranial hypertension safety update
Drug safety update: The MHRA has published a drug safety update on mesalazine.
Published: 5 December 2025
The Medicines and Healthcare products Regulatory Agency (MHRA) has published a drug safety update on mesalazine.
Idiopathic intracranial hypertension (IIH) has been very rarely reported in patients treated with mesalazine. Following a recent review, warnings for idiopathic intracranial hypertension are being added to the product information for all mesalazine products.
Further information and advice can be found on the MHRA website.